Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Angiogenesis Inhibitors，Ovarian Neoplasms”

16 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 16 results

Testing effectiveness (Phase 2)Study completedNCT00635193
What this trial is testing

Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)

Who this might be right for
Ovarian Cancer, Primary Peritoneal Cancer
AbbVie (prior sponsor, Abbott) 138
Testing effectiveness (Phase 2)Looking for participantsNCT06437353
What this trial is testing

Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

Who this might be right for
Ovarian Cancer
Anhui Provincial Cancer Hospital 74
Large-scale testing (Phase 3)Study completedNCT01204749
What this trial is testing

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
Amgen 919
Testing effectiveness (Phase 2)UnknownNCT04566952
What this trial is testing

Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian CancerOvarian and Fallopian Tube Cysts and NeoplasmsNeoplasms by Site+16 more
Xiaoxiang Chen 68
Testing effectiveness (Phase 2)Study completedNCT05494580
What this trial is testing

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Who this might be right for
Ovarian CancerOvarian CarcinomaPlatinum-resistant Ovarian Cancer+2 more
Sun Yat-sen University 29
Not applicableStudy completedNCT02825420
What this trial is testing

Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients

Who this might be right for
Relapsed Ovarian Cancer
PharmaMar 220
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06063070
What this trial is testing

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Who this might be right for
Ovarian CancerHigh Grade Serous Adenocarcinoma of OvaryHigh Grade Endometrioid Ovarian Cancer+2 more
Sun Yat-sen University 44
Testing effectiveness (Phase 2)UnknownNCT06161272
What this trial is testing

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Who this might be right for
Ovarian CancerHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal Carcinoma+1 more
Guangxi Medical University 80
Testing effectiveness (Phase 2)Study completedNCT01227928
What this trial is testing

Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women

Who this might be right for
Neoplasms, Ovarian
GlaxoSmithKline 145
Large-scale testing (Phase 3)Study completedNCT00327444
What this trial is testing

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Who this might be right for
Ovarian NeoplasmsAscites
Sanofi 58
Testing effectiveness (Phase 2)Ended earlyNCT01175772
What this trial is testing

Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy

Who this might be right for
Ovarian Carcinoma
HaEmek Medical Center, Israel 6
Testing effectiveness (Phase 2)UnknownNCT03262545
What this trial is testing

Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer

Who this might be right for
Angiogenesis Inhibitors，Ovarian Neoplasms
Sichuan Cancer Hospital and Research Institute 60
Testing effectiveness (Phase 2)UnknownNCT04556071
What this trial is testing

Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian NeoplasmsFallopian Tube NeoplasmsEndocrine Gland Neoplasms+21 more
Xiaoxiang Chen 32
Not applicableUnknownNCT06515678
What this trial is testing

Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension

Who this might be right for
Ovarian CancerAntiangiogenic-Associated HypertensionAdjuvant Bevacizumab+1 more
Groupe Hospitalier Pitie-Salpetriere 9,464
Large-scale testing (Phase 3)Study completedNCT00866697
What this trial is testing

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Ovarian Cancer
Novartis Pharmaceuticals 940
Large-scale testing (Phase 3)Looking for participantsNCT07472140
What this trial is testing

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancersPrimary Peritoneal Cancer
N.N. Alexandrov National Cancer Centre 120